Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.

Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, Lafayette R, Fowler MB, Arai S, Schrier S, Witteles RM.

JACC Heart Fail. 2019 Nov;7(11):958-966. doi: 10.1016/j.jchf.2019.07.007. Epub 2019 Oct 9.

PMID:
31606365
2.

Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.

Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB.

J Card Fail. 2012 Oct;18(10):804-9. doi: 10.1016/j.cardfail.2012.07.009.

PMID:
23040117
3.

Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?

Witteles RM, Fowler MB, Telli ML.

Heart Fail Clin. 2011 Jul;7(3):333-44. doi: 10.1016/j.hfc.2011.03.005. Epub 2011 May 14. Review.

PMID:
21749885
4.

Dyssynchrony Assessment with Tissue Doppler Imaging and Regional Volumetric Analysis by 3D Echocardiography Do Not Predict Long-Term Response to Cardiac Resynchronization Therapy.

Kuppahally SS, Fowler MB, Vagelos R, Wang P, Al-Ahmad A, Hsia H, Liang D.

Cardiol Res Pract. 2010 Dec 22;2011:568918. doi: 10.4061/2011/568918.

5.

Subclinical hypothyroidism. Risk factor for heart disease for over 40 years.

Savage RA, Savage S, Platts H, Platts A, Savage S, Fowler MB, Fowler G.

BMJ. 2010 Oct 26;341:c5990. doi: 10.1136/bmj.c5990. No abstract available.

PMID:
20978052
6.

Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.

Kao DP, Witteles RM, Quon A, Wu JC, Gambhir SS, Fowler MB.

J Am Coll Cardiol. 2010 Mar 2;55(9):926-7. doi: 10.1016/j.jacc.2009.08.085. No abstract available.

7.

Measurement precision in the optimization of cardiac resynchronization therapy.

Turcott RG, Witteles RM, Wang PJ, Vagelos RH, Fowler MB, Ashley EA.

Circ Heart Fail. 2010 May;3(3):395-404. doi: 10.1161/CIRCHEARTFAILURE.109.900076. Epub 2010 Feb 22.

8.

Worsening of left ventricular end-systolic volume and mitral regurgitation without increase in left ventricular dyssynchrony on acute interruption of cardiac resynchronization therapy.

Kuppahally SS, Fowler MB, Vagelos R, Wang P, Al-Ahmad A, Paloma A, Liang D.

Echocardiography. 2009 Aug;26(7):759-65. doi: 10.1111/j.1540-8175.2008.00887.x.

PMID:
19558521
9.

Hypertension, heart failure, and beta-adrenergic blocking drugs.

Fowler MB.

J Am Coll Cardiol. 2008 Sep 23;52(13):1073-5. doi: 10.1016/j.jacc.2008.06.032. No abstract available.

10.

Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.

Witteles RM, Fowler MB.

J Am Coll Cardiol. 2008 Jan 15;51(2):93-102. doi: 10.1016/j.jacc.2007.10.021. Review.

11.

Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.

Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB.

J Am Coll Cardiol. 2007 Nov 6;50(19):1835-40. Epub 2007 Oct 23.

12.

Why do we need to prevent right ventricular pacing?

Tsiperfal A, Scheibly K, Fowler MB, Chao C.

Prog Cardiovasc Nurs. 2007 Spring;22(2):108-9. No abstract available.

PMID:
17541323
13.

Beta-blocker dosing in community-based treatment of heart failure.

Fowler MB, Lottes SR, Nelson JJ, Lukas MA, Gilbert EM, Greenberg B, Massie BM, Abraham WT, Franciosa JA; COHERE Participant Physicians.

Am Heart J. 2007 Jun;153(6):1029-36.

PMID:
17540206
14.

Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.

Massie BM, Nelson JJ, Lukas MA, Greenberg B, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA; COHERE Participant Physicians.

Am J Cardiol. 2007 May 1;99(9):1263-8. Epub 2007 Mar 13.

PMID:
17478155
15.

Cardiomyopathy of insulin resistance.

Witteles RM, Fowler MB.

Heart Fail Clin. 2006 Jan;2(1):13-23. Review. No abstract available.

PMID:
17386873
16.

Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry.

Abraham WT, Massie BM, Lukas MA, Lottes SR, Nelson JJ, Fowler MB, Greenberg B, Gilbert EM, Franciosa JA; COHERE Participant Physicians.

Congest Heart Fail. 2007 Jan-Feb;13(1):16-21.

17.

Emerging therapies for the management of decompensated heart failure: from bench to bedside.

deGoma EM, Vagelos RH, Fowler MB, Ashley EA.

J Am Coll Cardiol. 2006 Dec 19;48(12):2397-409. Epub 2006 Nov 28. Review.

18.

Heart failure in community practice: relationship to age and sex in a beta-blocker registry.

Franciosa JA, Nelson JJ, Lukas MA, Lottes SR, Massie BM, Fowler MB, Greenberg B, Gilbert EM, Abraham WT; COHERE Participant Physicians.

Congest Heart Fail. 2006 Nov-Dec;12(6):317-23.

19.

Predictors of clinical outcomes in patients given carvedilol for heart failure.

Greenberg B, Lottes SR, Nelson JJ, Lukas MA, Fowler MB, Massie BM, Abraham WT, Gilbert EM, Franciosa JA; COHERE Participant Physicians.

Am J Cardiol. 2006 Dec 1;98(11):1480-4. Epub 2006 Oct 12.

PMID:
17126654
20.

The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.

Bell DS, Lukas MA, Holdbrook FK, Fowler MB.

Curr Med Res Opin. 2006 Feb;22(2):287-96.

PMID:
16466600
21.

Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.

Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Am Heart J. 2006 Jan;151(1):55-61.

PMID:
16368292
22.

B-type natriuretic peptide is effective therapy before care.

Witteles R, Matsuda K, Fowler MB.

Ann Intern Med. 2004 Dec 7;141(11):895. No abstract available.

PMID:
15583244
23.
24.

Care management for low-risk patients with heart failure: a randomized, controlled trial.

DeBusk RF, Miller NH, Parker KM, Bandura A, Kraemer HC, Cher DJ, West JA, Fowler MB, Greenwald G.

Ann Intern Med. 2004 Oct 19;141(8):606-13.

PMID:
15492340
25.

Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.

Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA.

Circulation. 2004 Sep 28;110(13):1780-6. Epub 2004 Sep 20.

PMID:
15381643
26.

The potential impact of soil ingestion on human mineral nutrition.

Hooda PS, Henry CJ, Seyoum TA, Armstrong LD, Fowler MB.

Sci Total Environ. 2004 Oct 15;333(1-3):75-87.

PMID:
15364520
27.

Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link.

Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB.

J Am Coll Cardiol. 2004 Jul 7;44(1):78-81.

28.
29.

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.

Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group.

J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9.

30.

NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.

Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I, Hoersch S, Katus HA.

Eur J Heart Fail. 2004 Mar 15;6(3):343-50.

31.

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

JAMA. 2003 Feb 12;289(6):712-8.

PMID:
12585949
32.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Circulation. 2002 Oct 22;106(17):2194-9.

PMID:
12390947
33.

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.

Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, Le Jemtel TH, Lachmann JS, Levine TB, Armstrong PW, Dec WG, Jessup M, Howlett J, Hershberger RE, Cohn JN, Adams KF Jr, Colucci WS, Warner-Stevenson L, Hosenpud JD, Bristow MR, Pina I, Baughman KL, Binkley PF, Ventura HO, Francis GS, White M, Miller LW, Berry B, Missov E.

Congest Heart Fail. 2002 Mar-Apr;8(2):98-124. No abstract available.

34.

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1--the medical history.

Leier CV, Silver MA, Massie BM, Young JB, Fowler MB, Ventura HO, Hershberger RE.

Congest Heart Fail. 2001 Sep-Oct;7(5):245-249. No abstract available.

35.

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.

Leier CV, Young JB, Levine TB, Pina I, Armstrong PW, Fowler MB, Warner-Stevenson L, Cohn JN, O'Connell JB, Bristow MR, Nicklas JM, Johnstone DE, Howlett J, Ventura HO, Giles TD, Greenberg BH, Chatterjee K, Bourge RC, Yancy CW, Gottleib SS.

Congest Heart Fail. 2001 Nov-Dec;7(6):297-308. No abstract available.

36.

Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure.

Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, Fowler MB.

J Am Coll Cardiol. 2002 Jan 2;39(1):70-8. Erratum in: J Am Coll Cardiol 2002 Feb 20;39(4):746.

37.

Effect of carvedilol on survival in severe chronic heart failure.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group.

N Engl J Med. 2001 May 31;344(22):1651-8.

38.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.

Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M.

J Am Coll Cardiol. 2001 May;37(6):1692-9.

39.

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M; U.S. Carvedilol Heart Failure Study Group.

N Engl J Med. 2001 May 3;344(18):1358-65.

40.

The role of angiotensin receptor blockers in the management of chronic heart failure.

Jamali AH, Tang WH, Khot UN, Fowler MB.

Arch Intern Med. 2001 Mar 12;161(5):667-72. Review.

PMID:
11231698
41.

Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited.

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB.

Am Heart J. 2000 Jan;139(1 Pt 1):78-84.

PMID:
10618566
42.

The influence of beta-adrenergic blocking drugs on morbidity and mortality in heart failure.

Fowler MB.

J Cardiovasc Risk. 1999 Jun;6(3):141-4. Review. No abstract available.

PMID:
10463139
43.

Cost effectiveness of carvedilol for heart failure.

Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G.

Am J Cardiol. 1999 Mar 15;83(6):890-6.

PMID:
10190405
44.

Spontaneous postpartum coronary dissection.

Lee FH, Yeung AC, Fowler MB, Fitzgerald PJ.

Circulation. 1999 Feb 9;99(5):721. No abstract available.

PMID:
9950672
45.

Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?

Fowler MB.

Eur Heart J. 1998 Dec;19 Suppl P:P17-25. Review.

PMID:
9886708
46.
47.

Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure.

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB.

Ann Intern Med. 1998 Aug 15;129(4):286-93.

PMID:
9729181
48.

Use of assumed versus measured oxygen consumption for the determination of cardiac output using the Fick principle.

Wolf A, Pollman MJ, Trindade PT, Fowler MB, Alderman EL.

Cathet Cardiovasc Diagn. 1998 Apr;43(4):372-80.

PMID:
9554760
49.

Effects of beta blockers on symptoms and functional capacity in heart failure.

Fowler MB.

Am J Cardiol. 1997 Dec 4;80(11A):55L-58L.

PMID:
9412543
50.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA.

J Card Fail. 1997 Sep;3(3):173-9.

PMID:
9330125

Supplemental Content

Loading ...
Support Center